학술논문

ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology
Document Type
article
Source
Acta Neuropathologica. 127(6)
Subject
Biomedical and Clinical Sciences
Neurosciences
Prevention
Genetics
Brain Disorders
Autoimmune Disease
Aging
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Neurodegenerative
Alzheimer's Disease
Acquired Cognitive Impairment
Dementia
Human Genome
Aetiology
2.1 Biological and endogenous factors
Neurological
Good Health and Well Being
Aged
80 and over
Cohort Studies
Databases as Topic
Endophenotypes
Genome-Wide Association Study
Hippocampus
Humans
Polymorphism
Single Nucleotide
Sclerosis
Sulfonylurea Compounds
Sulfonylurea Receptors
Oldest old
Neuropathology
KATP
CTAGE5
ADGC
Potassium channel
Alzheimer’ Disease Genetic Consortium
Clinical Sciences
Neurology & Neurosurgery
Language
Abstract
Hippocampal sclerosis of aging (HS-Aging) is a high-morbidity brain disease in the elderly but risk factors are largely unknown. We report the first genome-wide association study (GWAS) with HS-Aging pathology as an endophenotype. In collaboration with the Alzheimer's Disease Genetics Consortium, data were analyzed from large autopsy cohorts: (#1) National Alzheimer's Coordinating Center (NACC); (#2) Rush University Religious Orders Study and Memory and Aging Project; (#3) Group Health Research Institute Adult Changes in Thought study; (#4) University of California at Irvine 90+ Study; and (#5) University of Kentucky Alzheimer's Disease Center. Altogether, 363 HS-Aging cases and 2,303 controls, all pathologically confirmed, provided statistical power to test for risk alleles with large effect size. A two-tier study design included GWAS from cohorts #1-3 (Stage I) to identify promising SNP candidates, followed by focused evaluation of particular SNPs in cohorts #4-5 (Stage II). Polymorphism in the ATP-binding cassette, sub-family C member 9 (ABCC9) gene, also known as sulfonylurea receptor 2, was associated with HS-Aging pathology. In the meta-analyzed Stage I GWAS, ABCC9 polymorphisms yielded the lowest p values, and factoring in the Stage II results, the meta-analyzed risk SNP (rs704178:G) attained genome-wide statistical significance (p = 1.4 × 10(-9)), with odds ratio (OR) of 2.13 (recessive mode of inheritance). For SNPs previously linked to hippocampal sclerosis, meta-analyses of Stage I results show OR = 1.16 for rs5848 (GRN) and OR = 1.22 rs1990622 (TMEM106B), with the risk alleles as previously described. Sulfonylureas, a widely prescribed drug class used to treat diabetes, also modify human ABCC9 protein function. A subsample of patients from the NACC database (n = 624) were identified who were older than age 85 at death with known drug history. Controlling for important confounders such as diabetes itself, exposure to a sulfonylurea drug was associated with risk for HS-Aging pathology (p = 0.03). Thus, we describe a novel and targetable dementia risk factor.